Evidence map›Paper›PMID 41034468›Full record

ArticleCardiovascular engineering and technology2025

Enhancing Stroke Prevention in Transcatheter Aortic Valve Replacement: The Role of F2, a Novel Neuroprotection Device.

Mahsa Ghovvati, Taichiro Imahori, Nina Fukui, Kenichi Sakuta, Yoshiki Hanaoka, Lea Guo, Amir M Molaie, Aryan M Gajjar, Satoshi Tateshima, Gary Duckwiler and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular engineering and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mahsa GhovvatiDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0002-0608-5768
Taichiro ImahoriDepartment of Neurosurgery, Kitaharima Medical Center, Hyogo, Japan.
Nina FukuiDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Kenichi SakutaDepartment of Neurology, Jikei University School of Medicine, Tokyo, Japan.
Yoshiki HanaokaDepartment of Neurosurgery, Shinshu University School of Medicine, Matsumoto, Japan.
Lea GuoDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0001-9332-1441
Amir M MolaieDepartment of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Aryan M GajjarDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Satoshi TateshimaDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Gary DuckwilerDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Naoki KanekoDepartment of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. nkaneko@ucla.edu.ORCID 0000-0002-3579-7908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTranscatheter aortic valve replacement (TAVR) is an established treatment for severe aortic stenosis; however, it carries the risk of periprocedural strokes. Current cerebral embolic protection (CEP) devices, such as the Sentinel, provide partial protection but are limited by inadequate anatomical coverage and inability to capture smaller emboli effectively. This study aimed to evaluate the effectiveness of a novel CEP device, the F2 filter with a 28 μm pore size and full cervical vessel coverage, in preventing emboli from entering the cerebral circulation.

methodsThe Sentinel and F2 filter were evaluated for the ability to prevent embolic particles of various sizes (45-300 µm) from entering cerebral arteries using two in vitro flow models, incorporating standard and tortuous aortic anatomies. Additionally flow rates were also measured to confirm that normal perfusion was maintained while the devices were in place.

resultsThe F2 filter maintained normal cerebral arterial flow and significantly reduced the number of particles across all sizes compared to the Sentinel and control groups. This reduction was observed in all four cerebral branches and across both standard and tortuous aorta models.

conclusionsThe F2 filter showed superior neuroprotective effectiveness to prevent embolic debris from entering the cerebral circulation in the in vitro models. By offering comprehensive coverage to all cervical arteries and with a smaller mesh size, this filter has the potential to improve cerebral protection during TAVR.

Indexed as

Aortic ValveEmbolic Protection DevicesIntracranial EmbolismStrokeTranscatheter Aortic Valve ReplacementCerebrovascular CirculationHumansModels, CardiovascularProsthesis DesignCerebral embolic protection (CEP)Embolic debrisF2 filterStroke preventionTranscatheter aortic valve replacement (TAVR)

Identifiers

PMID41034468
PMCPMC12686061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.